OneSource Specialty Pharma (NSE:ONESOURCE) Research & Development: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:ONESOURCE OneSource Specialty Pharma Ltd NSE:ONESOURCE
8 GF Score
Price ₹1,483.60
! 3 Warning Signs
View Full Analysis

What is OneSource Specialty Pharma Research & Development?

OneSource Specialty Pharma NSE:ONESOURCE -2.14% 8 Research & Development is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:ONESOURCE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. OneSource Specialty Pharma's Research & Development for the three months ended in Jun. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

OneSource Specialty Pharma  (NSE:ONESOURCE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

OneSource Specialty Pharma Research & Development Related Terms

OneSource Specialty Pharma Research & Development Historical Data

* Premium members only.

The historical data trend for OneSource Specialty Pharma's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OneSource Specialty Pharma Research & Development Chart

OneSource Specialty Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Research & Development
0.00 0.00 20.49 0.00

OneSource Specialty Pharma Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:ONESOURCE
8GF Score
OneSource Specialty Pharma Ltd NSE:ONESOURCE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OneSource Specialty Pharma Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
OneSource Specialty Pharma (NSE:ONESOURCE) has a Research & Development of ₹0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on OneSource Specialty Pharma and its competitors.
Is OneSource Specialty Pharma's Research & Development too high?
OneSource Specialty Pharma's current Research & Development is ₹0 Mil. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's Research & Development compare to VRTX and REGN?
OneSource Specialty Pharma's Research & Development of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on OneSource Specialty Pharma and its competitors. OneSource Specialty Pharma's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current Research & Development of ₹0 Mil. The current Research & Development is ₹0 Mil. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current Research & Development is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OneSource Specialty Pharma Business Description

Other Exchanges 544292:India
Address Bannerghatta Road, Star 1, Opp IIM Bangalore, Bilekahalli, Bangalore, KA, IND, 560076
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score

Get the complete analysis for NSE:ONESOURCE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,483.60
Price